--- title: "Lifeward names Ronen Tsimerman chief financial officer" url: "https://aibio.space/news/lifeward-names-ronen-tsimerman-chief-financial-officer/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-10-27" section: "Company Updates" tickers: "NASDAQ:LFWD, NASDAQ:ICCM" source: "https://www.sec.gov/Archives/edgar/data/1607962/000117891326004856/zk2636265.htm" summary: "The board appointed Ronen Tsimerman as chief financial officer, effective November 1, 2026. His employment agreement is subject to shareholder approval of" --- By the aibio.space news desk. Sources - [Lifeward Ltd. 8-K (2026-10-27)](https://www.sec.gov/Archives/edgar/data/1607962/000117891326004856/zk2636265.htm) - [Lifeward Ltd. financial data (SEC XBRL)](https://www.sec.gov/Archives/edgar/data/1607962/000117891326001208/) [LFWD](https://aibio.space/companies/lifeward/) [ICCM](https://aibio.space/companies/icecure-medical/) 2026-10-27 # Lifeward names Ronen Tsimerman chief financial officer Tickers [LFWD](https://aibio.space/companies/lifeward/)[ICCM](https://aibio.space/companies/icecure-medical/) The board appointed Ronen Tsimerman as chief financial officer, effective November 1, 2026. His employment agreement is subject to shareholder approval of a renewed compensation policy. ## Key facts - **Companies**: Lifeward Ltd. (NASDAQ: LFWD), IceCure Medical Ltd. (NASDAQ: ICCM) - **News type**: Company Updates - **Primary source**: [Lifeward Ltd. 8-K (2026-10-27)](https://www.sec.gov/Archives/edgar/data/1607962/000117891326004856/zk2636265.htm) *The eyepieces of a laboratory microscope. CC0, via rawpixel. The picture shows the field, not the companies named.* Lifeward Ltd. said in a Form 8-K filed October 27, 2026 that its board of directors appointed Ronen Tsimerman as the company's chief financial officer, principal financial officer and principal accounting officer. The board made the appointment on October 26, 2026, and it takes effect November 1, 2026. Josh Hexter, the company's interim chief executive officer, signed the filing. Lifeward is based in Hudson, MA, is incorporated in Israel, and trades on the Nasdaq Capital Market under the symbol LFWD. ## Who Tsimerman is The filing describes Tsimerman, age 56, as an experienced global finance executive. He most recently served as chief financial officer of Scopio Labs Ltd. from August through October 2026. Before that, he was chief financial officer of IceCure Medical Ltd (Nasdaq: [ICCM](https://aibio.space/companies/icecure-medical/)) from May 2017 to August 2026, and he was its chief operating officer from May 2018 to November 2025. His earlier roles include chief financial officer of Insuline Medical Ltd. (TASE: INSL) from May 2015 to May 2017, and chief financial officer of the Mer-Group Broadband division (TASE: CMER) from 2005 to 2013. He was vice president of finance of the Mer-Group Telecom Division from 2013 to 2014. The filing says he received a bachelor's degree in business and an MBA from the College of Management in Israel. ## The terms The company and Tsimerman will enter into an employment agreement. The filing says that agreement is subject to shareholder approval of Lifeward's renewed compensation policy at its upcoming annual general meeting, which is to be held on October 30, 2026. Under the agreement, Tsimerman will receive a gross monthly base salary of NIS 70,000. He will also be eligible for an annual performance-based bonus, set each year by the compensation committee and the board, with a target amount of not less than four monthly salaries. The agreement also provides for a transaction bonus. The filing says all bonuses are subject to the renewed compensation policy and any required approvals. The agreement provides a 3-month notice period for termination. That period increases to four months for either party following any change in the company's chief executive officer, including the appointment of a permanent chief executive officer. The company also entered into its standard indemnification, insurance and exculpation agreement with Tsimerman. The filing states that he has no family relationship with any director or executive officer of the company. Apart from his compensation arrangements, the filing says there are no arrangements or understandings between him and any other person under which he was appointed. It also reports no transactions requiring disclosure under Item 404(a) of Regulation S-K. ## Financial position Lifeward's annual report on Form 10-K, filed March 18, 2026, reported revenue of $22.0 million for 2025 and $25.7 million for 2024. Research and development expense was $3.2 million for 2025 and $4.6 million for 2024. The net loss was $19.9 million for 2025 and $28.9 million for 2024. Cash from operations was negative $16.8 million for 2025 and negative $21.7 million for 2024. Year-end cash and cash equivalents were $2.2 million at December 31, 2025 and $6.7 million at December 31, 2024. The company's quarterly report on Form 10-Q shows cash and cash equivalents of $9.4 million at June 30, 2026. The filing says nothing about why the post is changing hands or about the former CFO. The size and trigger of the transaction bonus are not stated. ## What the filing leaves open The hire arrives with the company under pressure. Revenue fell to $22.0 million in 2025 from $25.7 million in 2024, the net loss was $19.9 million, and operations used $16.8 million of cash against year-end cash of $2.2 million. Cash was $9.4 million at June 30, 2026. The company is also led by an interim chief executive; the CFO's notice period lengthens to four months after any change in chief executive. Tsimerman's most recent post at Scopio Labs lasted from August through October 2026, a short stay. His employment agreement depends on shareholders approving the renewed compensation policy at the October 30, 2026 meeting, and the filing does not say what happens if they vote it down. His appointment takes effect on November 1, 2026. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story LFWD Lifeward Ltd. NASDAQ · United States Open the starter desk ICCM IceCure Medical Ltd. NASDAQ · United States Open the starter desk ## More in Company Updates Company Updates ### [PTC reports third-quarter 2026 revenue of $358 million and raises product guidance](https://aibio.space/news/ptc-reports-third-quarter-2026-revenue-358-million-raises-product/) Oct 29, 2026 Company Updates ### [Processa clears VT-7208 CSU IND and names a new executive chair](https://aibio.space/news/processa-clears-vt-7208-csu-ind-names-new-executive-chair/) Oct 29, 2026 Company Updates ### [Kiora in-licenses late-stage KIO-401 for retinal artery occlusion](https://aibio.space/news/kiora-licenses-late-stage-kio-401-retinal-artery-occlusion/) Oct 29, 2026 --- Source page: https://aibio.space/news/lifeward-names-ronen-tsimerman-chief-financial-officer/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Lifeward names Ronen Tsimerman chief financial officer", 2026-10-27, https://aibio.space/news/lifeward-names-ronen-tsimerman-chief-financial-officer/